vs
OPTICAL CABLE CORP（OCC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是OPTICAL CABLE CORP的1.5倍（$30.3M vs $19.8M），OPTICAL CABLE CORP净利率更高（0.2% vs -221.3%，领先221.6%），REGENXBIO Inc.同比增速更快（43.0% vs 1.8%），OPTICAL CABLE CORP自由现金流更多（$718.8K vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 15.5%）
光电缆公司总部位于弗吉尼亚州罗阿诺克，主营光纤光缆生产，产品主要应用于电信领域，销售覆盖美国及全球70余个国家，同时也为美国军方生产陆战战术光纤光缆。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
OCC vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.5倍
$19.8M
营收增速更快
RGNX
高出41.2%
1.8%
净利率更高
OCC
高出221.6%
-221.3%
自由现金流更多
OCC
多$53.5M
$-52.8M
两年增速更快
RGNX
近两年复合增速
15.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.8M | $30.3M |
| 净利润 | $48.6K | $-67.1M |
| 毛利率 | 31.9% | — |
| 营业利润率 | 1.4% | -190.0% |
| 净利率 | 0.2% | -221.3% |
| 营收同比 | 1.8% | 43.0% |
| 净利润同比 | -87.0% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OCCRGNX
| Q4 25 | $19.8M | $30.3M | ||
| Q3 25 | $19.9M | $29.7M | ||
| Q2 25 | $17.5M | $21.4M | ||
| Q1 25 | $15.7M | $89.0M | ||
| Q4 24 | $19.5M | $21.2M | ||
| Q3 24 | $16.2M | $24.2M | ||
| Q2 24 | $16.1M | $22.3M | ||
| Q1 24 | $14.9M | $15.6M |
净利润OCCRGNX
| Q4 25 | $48.6K | $-67.1M | ||
| Q3 25 | $301.9K | $-61.9M | ||
| Q2 25 | $-697.9K | $-70.9M | ||
| Q1 25 | $-1.1M | $6.1M | ||
| Q4 24 | $373.5K | $-51.2M | ||
| Q3 24 | $-1.6M | $-59.6M | ||
| Q2 24 | $-1.6M | $-53.0M | ||
| Q1 24 | $-1.4M | $-63.3M |
毛利率OCCRGNX
| Q4 25 | 31.9% | — | ||
| Q3 25 | 31.7% | — | ||
| Q2 25 | 30.4% | — | ||
| Q1 25 | 29.4% | — | ||
| Q4 24 | 33.5% | 70.2% | ||
| Q3 24 | 24.2% | 48.8% | ||
| Q2 24 | 25.1% | 52.5% | ||
| Q1 24 | 25.0% | 72.6% |
营业利润率OCCRGNX
| Q4 25 | 1.4% | -190.0% | ||
| Q3 25 | 2.8% | -176.3% | ||
| Q2 25 | -2.4% | -296.3% | ||
| Q1 25 | -5.4% | 13.6% | ||
| Q4 24 | 3.4% | -242.1% | ||
| Q3 24 | -8.2% | -256.6% | ||
| Q2 24 | -8.1% | -251.3% | ||
| Q1 24 | -9.4% | -408.8% |
净利率OCCRGNX
| Q4 25 | 0.2% | -221.3% | ||
| Q3 25 | 1.5% | -208.3% | ||
| Q2 25 | -4.0% | -331.8% | ||
| Q1 25 | -7.0% | 6.8% | ||
| Q4 24 | 1.9% | -241.3% | ||
| Q3 24 | -9.6% | -246.3% | ||
| Q2 24 | -9.9% | -237.7% | ||
| Q1 24 | -9.6% | -405.4% |
每股收益（稀释后）OCCRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | $-0.18 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $237.5K | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $16.5M | $102.7M |
| 总资产 | $40.1M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OCCRGNX
| Q4 25 | $237.5K | $230.1M | ||
| Q3 25 | $421.4K | $274.2M | ||
| Q2 25 | $894.3K | $323.3M | ||
| Q1 25 | $128.3K | $267.9M | ||
| Q4 24 | $244.2K | $234.7M | ||
| Q3 24 | $796.7K | $255.5M | ||
| Q2 24 | $1.1M | $290.4M | ||
| Q1 24 | $221.0K | $338.7M |
股东权益OCCRGNX
| Q4 25 | $16.5M | $102.7M | ||
| Q3 25 | $18.2M | $161.5M | ||
| Q2 25 | $19.1M | $213.7M | ||
| Q1 25 | $19.7M | $274.2M | ||
| Q4 24 | $20.8M | $259.7M | ||
| Q3 24 | $20.4M | $301.4M | ||
| Q2 24 | $21.8M | $348.3M | ||
| Q1 24 | $23.3M | $390.7M |
总资产OCCRGNX
| Q4 25 | $40.1M | $453.0M | ||
| Q3 25 | $40.2M | $525.2M | ||
| Q2 25 | $39.1M | $581.0M | ||
| Q1 25 | $37.8M | $490.9M | ||
| Q4 24 | $40.4M | $466.0M | ||
| Q3 24 | $37.6M | $519.1M | ||
| Q2 24 | $39.9M | $569.4M | ||
| Q1 24 | $40.5M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $797.3K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $718.8K | $-52.8M |
| 自由现金流率自由现金流/营收 | 3.6% | -174.0% |
| 资本支出强度资本支出/营收 | 0.4% | 1.7% |
| 现金转化率经营现金流/净利润 | 16.40× | — |
| 过去12个月自由现金流最近4个季度 | $1.1M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流OCCRGNX
| Q4 25 | $797.3K | $-52.3M | ||
| Q3 25 | $-2.2M | $-56.0M | ||
| Q2 25 | $141.4K | $-49.3M | ||
| Q1 25 | $2.7M | $33.6M | ||
| Q4 24 | $-1.5M | $-31.6M | ||
| Q3 24 | $552.4K | $-40.5M | ||
| Q2 24 | $373.7K | $-45.5M | ||
| Q1 24 | $-261.1K | $-55.5M |
自由现金流OCCRGNX
| Q4 25 | $718.8K | $-52.8M | ||
| Q3 25 | $-2.3M | $-56.5M | ||
| Q2 25 | $73.4K | $-49.7M | ||
| Q1 25 | $2.6M | $32.6M | ||
| Q4 24 | $-1.6M | $-32.7M | ||
| Q3 24 | $475.2K | $-40.9M | ||
| Q2 24 | $218.2K | $-46.0M | ||
| Q1 24 | $-341.5K | $-56.0M |
自由现金流率OCCRGNX
| Q4 25 | 3.6% | -174.0% | ||
| Q3 25 | -11.4% | -189.9% | ||
| Q2 25 | 0.4% | -232.8% | ||
| Q1 25 | 16.5% | 36.6% | ||
| Q4 24 | -8.1% | -154.2% | ||
| Q3 24 | 2.9% | -168.9% | ||
| Q2 24 | 1.4% | -206.2% | ||
| Q1 24 | -2.3% | -358.5% |
资本支出强度OCCRGNX
| Q4 25 | 0.4% | 1.7% | ||
| Q3 25 | 0.4% | 1.7% | ||
| Q2 25 | 0.4% | 1.8% | ||
| Q1 25 | 0.5% | 1.2% | ||
| Q4 24 | 0.3% | 5.1% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 1.0% | 2.1% | ||
| Q1 24 | 0.5% | 3.6% |
现金转化率OCCRGNX
| Q4 25 | 16.40× | — | ||
| Q3 25 | -7.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | -4.08× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OCC
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
